Prevail Therapeutics Inc. - common stock (PRVL): Price and Financial Metrics


Prevail Therapeutics Inc. - common stock (PRVL)

Today's Latest Price: $10.72 USD

0.33 (3.18%)

Updated Oct 27 6:55pm

Add PRVL to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 384 in Biotech

See all "A" rated Strong Buy stocks

PRVL Stock Price Chart Interactive Chart >

Price chart for PRVL

PRVL Price/Volume Stats

Current price $10.72 52-week high $19.96
Prev. close $10.39 52-week low $9.02
Day low $10.41 Volume 253,900
Day high $10.83 Avg. volume 161,659
50-day MA $11.16 Dividend yield N/A
200-day MA $14.38 Market Cap 366.78M

Prevail Therapeutics Inc. - common stock (PRVL) Company Bio


Prevail Therapeutics, Inc. develops therapeutics for neurodegenerative diseases. The firm engages in the research and development of novel biologic gene therapies to treat Parkinson's disease and other neurodegenerative diseases. The company was founded by Asa Abeliovich on July 6, 2017 and is headquartered in New York, NY.


PRVL Latest News Stream


Event/Time News Detail
Loading, please wait...

PRVL Latest Social Stream


Loading social stream, please wait...

View Full PRVL Social Stream

Latest PRVL News From Around the Web

Below are the latest news stories about Prevail Therapeutics Inc that investors may wish to consider to help them evaluate PRVL as an investment opportunity.

Prevail Therapeutics Inc. (PRVL) Investor Presentation - Slideshow

The following slide deck was published by Prevail Therapeutics Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 14, 2020

Earnings Scheduled For August 11, 2020

Companies Reporting Before The Bell • NIO Inc. (NYSE: NIO ) is estimated to report quarterly loss at $0.26 per share on revenue of $503.58 million. • Sysco Inc. (NYSE: SYY ) is expected to report quarterly loss at $0.30 per share on revenue of $9.52 billion. • Affimed Inc. (NASDAQ: AFMD ) is expected to report quarterly loss at $0.16 per share on revenue of $5.52 million. • BioNTech Inc. (NASDAQ: BNTX ) is estimated to report quarterly loss at $0.28 per share on revenue of $52.23 million. • CSP Inc. (NASDAQ: CSPI ) is expected to report earnings for its third quarter. • Casper Sleep Inc. (NYSE: CSPR ) is expected to report quarterly loss at $0.76 per share on revenue of $104.75 million. • eMagin Corporation Common Stock Inc. (AMEX: EMAN ) is expected to report earnings for its second qu...

Benzinga | August 11, 2020

Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006

Gene Therapy is Being Developed for the Treatment of Frontotemporal Dementia patients with GRN Mutations

GlobeNewswire | July 27, 2020

Why Prevail Therapeutics Is Trading Higher Today

Prevail Therapeutics (NASDAQ: PRVL ) shares are trading higher on Thursday after the company reported it will highlight multiple gene therapy programs for neurodegenerative diseases at the 2020 Alzheimer's Association International Conference. Prevail … Full story available on Benzinga.com

Benzinga | July 23, 2020

Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer’s Association International Conference

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company…

GlobeNewswire | July 22, 2020

Read More 'PRVL' Stories Here

PRVL Price Returns

1-mo 0.37%
3-mo -26.83%
6-mo -27.42%
1-year -7.03%
3-year N/A
5-year N/A
YTD -32.28%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6562 seconds.